$3.79
-0.25-6.08%
Last update: Nov 13, 3:10 PM
Oramed Pharmaceuticals Inc
ORMPNASDAQ
Oramed Pharmaceuticals rose 67.9% from $2.40 to $4.03, ahead of the S&P 500's +12.7%. Its worst day was May 22 (−8.9%), and its low came Nov 14 at $2.33.
Nov 13, 2025 – Nov 12, 2026 · picked from earnings, analyst actions, headlines and the biggest daily moves
EPS of $1.26 beat the $-0.08 estimate on $2.0M revenue.
−2.9% · S&P 500 0.0%
Oramed Pharmaceuticals shares rose 11.2%, while the S&P 500 rose 0.9%.
+11.2% · S&P 500 +0.9%
Story events cover the past 12 months · Times ET
EPS of $0.24 beat the $-0.03 estimate on $0.00 revenue.
−5.1% · S&P 500 −1.8%
Oramed Pharmaceuticals shares rose 13.0%, while the S&P 500 rose 0.2%.
+13.0% · S&P 500 +0.2%
EPS of $0.91 beat the $-0.08 estimate on $0.00 revenue.
−1.2% · S&P 500 +1.0%
Oramed Pharmaceuticals shares rose 16.3%, while the S&P 500 rose 0.1%.
+16.3%, the year's best day · S&P 500 +0.1%
EPS of $1.84 beat the $0.43 estimate on $0.00 revenue.
+1.2% · S&P 500 −0.3%
Oramed Pharmaceuticals closed at its highest level of the year, 122.5% above where the year started.
+2.5% · S&P 500 0.0%
Where it ended: a close of $4.03 on Nov 12, 2026.
Nothing in the past 12 months.
All ORMP analyst actionsNothing in the past 12 months.
All ORMP dividend historyChart by ChartIQ. Events, ratings, quote and fundamentals from Benzinga APIs. Daily bars for ORMP and SPY from Benzinga historical bars. Not investment advice.
